# ACP-204 in Adults With Alzheimer's Disease Psychosis

> **NCT06159673** · PHASE2,PHASE3 · RECRUITING · sponsor: **ACADIA Pharmaceuticals Inc.** · enrollment: 1074 (estimated)

## Conditions studied

- Alzheimer's Disease Psychosis

## Interventions

- **DRUG:** ACP-204
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06159673
- **Lead sponsor:** ACADIA Pharmaceuticals Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-11-14
- **Primary completion:** 2028-01
- **Final completion:** 2028-02
- **Target enrollment:** 1074 (ESTIMATED)
- **Last updated:** 2026-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06159673

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06159673, "ACP-204 in Adults With Alzheimer's Disease Psychosis". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06159673. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*